227 related articles for article (PubMed ID: 3076761)
1. Immunotherapy of cancer using interleukin 2: current status and future prospects.
Rosenberg SA
Immunol Today; 1988 Feb; 9(2):58-62. PubMed ID: 3076761
[No Abstract] [Full Text] [Related]
2. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Rosenberg SA
Important Adv Oncol; 1986; ():55-91. PubMed ID: 3330541
[No Abstract] [Full Text] [Related]
3. [Use of interleukin 2-activated lymphocytes (LAK cells) in adoptive immunotherapy of neoplasms].
Robak T
Pol Tyg Lek; 1988 Nov; 43(47):1491-5. PubMed ID: 3266975
[No Abstract] [Full Text] [Related]
4. Adoptive immunotherapy in gastrointestine malignancies using interleukin-2. Current results and future prospects.
Marshall GD
Acta Chir Scand Suppl; 1989; 549():71-4. PubMed ID: 2784605
[No Abstract] [Full Text] [Related]
5. [Prospects for cancer immunotherapy using interleukin-1(IL-1) and interleukin-2(IL-2)].
Okuno K
Nihon Rinsho; 1983; 41(4):868-74. PubMed ID: 6350655
[No Abstract] [Full Text] [Related]
6. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.
Rosenberg S
J Natl Cancer Inst; 1985 Oct; 75(4):595-603. PubMed ID: 3876465
[No Abstract] [Full Text] [Related]
7. [Adoptive immunotherapy: a new therapeutic approach to cancer based on interleukin 2].
Sculier JP; Bron D; Delforge A; Stryckmans P; Klastersky J
Rev Med Brux; 1987 Mar; 8(3):133-9. PubMed ID: 3495843
[No Abstract] [Full Text] [Related]
8. [Interleukin 2].
Taguchi T; Kimoto Y
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1203-7. PubMed ID: 3495239
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of cancer: the end of the beginning?
Durant JR
N Engl J Med; 1987 Apr; 316(15):939-41. PubMed ID: 3493434
[No Abstract] [Full Text] [Related]
10. Natural killer cell-based immunotherapy in cancer: current insights and future prospects.
Sutlu T; Alici E
J Intern Med; 2009 Aug; 266(2):154-81. PubMed ID: 19614820
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 and lymphokine-activated killer cell therapy for gastrointestinal cancer.
Guillou P
Acta Chir Scand Suppl; 1989; 549():26-30. PubMed ID: 2784604
[No Abstract] [Full Text] [Related]
12. [The activation of natural killer cells. A new approach to adoptive immunotherapy of tumors].
Schwarz R
Fortschr Med; 1988 Oct; 106(29):579-80. PubMed ID: 3266178
[No Abstract] [Full Text] [Related]
13. The current status and future applications of interleukin 2- and adoptive immunotherapy in cancer treatment.
Simpson C; Seipp CA; Rosenberg SA
Semin Oncol Nurs; 1988 May; 4(2):132-41. PubMed ID: 3287538
[No Abstract] [Full Text] [Related]
14. [Using LAK cells in the adoptive immunotherapy in cancers].
Urushizaki I
Rinsho Ketsueki; 1987 Oct; 28(10):1897-8. PubMed ID: 3502569
[No Abstract] [Full Text] [Related]
15. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
Kimoto Y; Taguchi T
Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
[TBL] [Abstract][Full Text] [Related]
16. Biological response modifiers in renal cancer.
Ackermann R
Prog Clin Biol Res; 1988; 269():313-28. PubMed ID: 2455907
[No Abstract] [Full Text] [Related]
17. Role of natural killer cells in defense against leukemia: therapeutic considerations.
Lotzová E
Nat Immun Cell Growth Regul; 1988; 7(3):170-9. PubMed ID: 3262822
[No Abstract] [Full Text] [Related]
18. Adoptive immunotherapy of cancer with activated lymphocytes and interleukin-2.
Kradin RL; Kurnick JT
Pathol Immunopathol Res; 1986; 5(3-5):193-202. PubMed ID: 3299346
[No Abstract] [Full Text] [Related]
19. [Immunotherapy of cancer with interleukin-2 and with interleukin-2 activated cells].
Osanto S; Brand A; van Rood JJ; Cleton FJ
Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1392-5. PubMed ID: 2677758
[No Abstract] [Full Text] [Related]
20. [Adoptive immunotherapy of malignant diseases using normal allogeneic LAK cells].
Kimoto Y; Tanji Y; Tanaka T; Taguchi T
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1884-9. PubMed ID: 3496050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
